Regulatory Mechanism of HIF-1α and Its Role in Liver Diseases: a Narrative Review

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2022 Mar 14

PMID 35282052

Authors

Qingfei Chu

Xinyu Gu

Qiuxian Zheng

Haihong Zhu

Affiliations

Soon will be listed here.

Abstract

Objective: To summarize the structure, regulatory mechanism, and target genes of hypoxia-inducible factor-1 alpha (HIF-1α) and to comprehensively expound its role in various chronic liver diseases, thus providing a new perspective on the treatment of various liver diseases.

Background: Liver disease, especially chronic liver disease, is a long-standing public health problem; the mortality rate due to end-stage cirrhosis and liver cancer is high worldwide and continues to grow. Moreover, there is a lack of effective targeted therapy for most liver diseases, such as fatty liver, alcoholic liver disease (ALD), and advanced liver cancer, for which drug treatment approaches are extremely limited. As the liver is a highly aerobic organ, an insufficient oxygen supply can induce a series of diseases, and HIF proteins play an important role in these processes.

Methods: Literature on HIF-1α and its effects on various liver diseases were extensively searched, and the feasibility and challenges of targeting HIF-1α to treat various chronic liver diseases were analyzed.

Conclusions: HIF-1α is widely involved in the occurrence, development, and prognosis of ALD, nonalcoholic fatty liver disease (NAFLD), acetaminophen (APAP)-induced liver injury (AILI), viral hepatitis, hepatocellular carcinoma (HCC), and other liver diseases. HIF-1α participates in complex signaling pathways, and its expression is regulated in many liver diseases. These results suggest the feasibility and clinical significance of targeting HIF-1α to treat liver diseases.

Citing Articles

Serum proteomic and metabolomic profiling of hepatocellular carcinoma patients co-infected with .

Tang Z, Wei C, Deng X, Lin Q, Hu Q, Li S Front Immunol. 2025; 15():1489077.

PMID: 39840062 PMC: 11746118. DOI: 10.3389/fimmu.2024.1489077.

The Physiological Functions and Therapeutic Potential of Hypoxia-Inducible Factor-1α in Vascular Calcification.

Zhang Z, Wang D, Xu R, Li X, Wang Z, Zhang Y Biomolecules. 2025; 14(12.

PMID: 39766299 PMC: 11674127. DOI: 10.3390/biom14121592.

Machine Perfusion as a Strategy to Decrease Ischemia-Reperfusion Injury and Lower Cancer Recurrence Following Liver Transplantation.

Garcia K, Hussein A, Satish S, Wehrle C, Karakaya O, Panconesi R Cancers (Basel). 2024; 16(23).

PMID: 39682147 PMC: 11639801. DOI: 10.3390/cancers16233959.

Unveiling the Impact of BMP9 in Liver Diseases: Insights into Pathogenesis and Therapeutic Potential.

Chen H, Li Y, Nio K, Tang H Biomolecules. 2024; 14(8).

PMID: 39199400 PMC: 11353080. DOI: 10.3390/biom14081013.

Pharmacological induction of the hypoxia response pathway in Huh7 hepatoma cells limits proliferation but increases resilience under metabolic stress.

Jacquemin C, El Orch W, Diaz O, Lalande A, Aublin-Gex A, Jacolin F Cell Mol Life Sci. 2024; 81(1):320.

PMID: 39078527 PMC: 11335246. DOI: 10.1007/s00018-024-05361-6.

References

Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal W, Strowig T . Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482(7384):179-85. PMC: 3276682. DOI: 10.1038/nature10809. View

Satishchandran A, Ambade A, Rao S, Hsueh Y, Iracheta-Vellve A, Tornai D . MicroRNA 122, Regulated by GRLH2, Protects Livers of Mice and Patients From Ethanol-Induced Liver Disease. Gastroenterology. 2017; 154(1):238-252.e7. PMC: 5742049. DOI: 10.1053/j.gastro.2017.09.022. View

Shao G, Zou Y, Lucatelli P, Tsilimigras D, Shimise S, Kawaguchi T . Chinese expert consensus on technical recommendations for the standard operation of drug-eluting beads for transvascular embolization. Ann Transl Med. 2021; 9(8):714. PMC: 8106009. DOI: 10.21037/atm-21-1678. View

Bharadwaj L, Davies G, Xavier I, Ovsenek N . l-carnosine and verapamil inhibit hypoxia-induced expression of hypoxia inducible factor (HIF-1 alpha) in H9c2 cardiomyoblasts. Pharmacol Res. 2002; 45(3):175-81. DOI: 10.1006/phrs.2001.0911. View

Palazon A, Goldrath A, Nizet V, Johnson R . HIF transcription factors, inflammation, and immunity. Immunity. 2014; 41(4):518-28. PMC: 4346319. DOI: 10.1016/j.immuni.2014.09.008. View

Laitakari A, Tapio J, Makela K, Herzig K, Dengler F, Gylling H . HIF-P4H-2 inhibition enhances intestinal fructose metabolism and induces thermogenesis protecting against NAFLD. J Mol Med (Berl). 2020; 98(5):719-731. PMC: 7220983. DOI: 10.1007/s00109-020-01903-0. View

Andrade R, Chalasani N, Bjornsson E, Suzuki A, Kullak-Ublick G, Watkins P . Drug-induced liver injury. Nat Rev Dis Primers. 2019; 5(1):58. DOI: 10.1038/s41572-019-0105-0. View

Yu G, Chen X, Chen S, Ye W, Hou K, Liang M . Arsenic trioxide reduces chemo-resistance to 5-fluorouracil and cisplatin in HBx-HepG2 cells via complex mechanisms. Cancer Cell Int. 2015; 15:116. PMC: 4676851. DOI: 10.1186/s12935-015-0269-y. View

Luo F, Zou Z, Liu X, Ling M, Wang Q, Wang Q . Enhanced glycolysis, regulated by HIF-1α via MCT-4, promotes inflammation in arsenite-induced carcinogenesis. Carcinogenesis. 2017; 38(6):615-626. DOI: 10.1093/carcin/bgx034. View

10.

Wang X, Wu D, Yang L, Gan L, Cederbaum A . Cytochrome P450 2E1 potentiates ethanol induction of hypoxia and HIF-1α in vivo. Free Radic Biol Med. 2013; 63:175-86. PMC: 3729858. DOI: 10.1016/j.freeradbiomed.2013.05.009. View

11.

Platko K, Lebeau P, Byun J, Poon S, Day E, MacDonald M . GDF10 blocks hepatic PPARγ activation to protect against diet-induced liver injury. Mol Metab. 2019; 27:62-74. PMC: 6717799. DOI: 10.1016/j.molmet.2019.06.021. View

12.

Xie C, Yagai T, Luo Y, Liang X, Chen T, Wang Q . Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. Nat Med. 2017; 23(11):1298-1308. PMC: 6410352. DOI: 10.1038/nm.4412. View

13.

Zhong Z, Ramshesh V, Rehman H, Currin R, Sridharan V, Theruvath T . Activation of the oxygen-sensing signal cascade prevents mitochondrial injury after mouse liver ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol. 2008; 295(4):G823-32. PMC: 2575910. DOI: 10.1152/ajpgi.90287.2008. View

14.

Moon J, Welch T, Gonzalez F, Copple B . Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2009; 296(3):G582-92. PMC: 2660171. DOI: 10.1152/ajpgi.90368.2008. View

15.

Meng X, Franklin D, Dong J, Zhang Y . MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res. 2014; 74(24):7161-7. PMC: 4504428. DOI: 10.1158/0008-5472.CAN-14-1446. View

16.

Nishiyama Y, Goda N, Kanai M, Niwa D, Osanai K, Yamamoto Y . HIF-1α induction suppresses excessive lipid accumulation in alcoholic fatty liver in mice. J Hepatol. 2011; 56(2):441-7. DOI: 10.1016/j.jhep.2011.07.024. View

17.

Louvet A, Mathurin P . Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol. 2015; 12(4):231-42. DOI: 10.1038/nrgastro.2015.35. View

18.

Kang J, Chun Y, Huh J, Park J . FIH permits NAA10 to catalyze the oxygen-dependent lysyl-acetylation of HIF-1α. Redox Biol. 2018; 19:364-374. PMC: 6142190. DOI: 10.1016/j.redox.2018.09.002. View

19.

Shibata T, Aburatani H . Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol. 2014; 11(6):340-9. DOI: 10.1038/nrgastro.2014.6. View

20.

Wang Z, Li B, Jiang H, Ma Y, Bao Y, Zhu X . IL-8 exacerbates alcohol-induced fatty liver disease via the Akt/HIF-1α pathway in human IL-8-expressing mice. Cytokine. 2020; 138:155402. DOI: 10.1016/j.cyto.2020.155402. View